Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus OGEN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus OGEN 5.
ESTRADIOL CYPIONATE vs OGEN 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol cypionate is a synthetic ester of estradiol, a form of estrogen. It binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and leading to effects such as development of female secondary sexual characteristics, regulation of menstrual cycle, and maintenance of reproductive tissues. It also has effects on bone density, lipid metabolism, and coagulation factors.
Estrogen replacement; binds to estrogen receptors, activating gene transcription for estrogenic effects in target tissues.
1-5 mg intramuscularly every 3-4 weeks.
0.625 mg orally once daily, adjusted based on response.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 days following intramuscular injection, reflecting prolonged absorption from the oil depot.
Terminal elimination half-life of estrone (primary active metabolite) is approximately 20 hours; steady-state concentrations achieved within 6-8 days. Half-life of estradiol is shorter (1-2 hours) but clinically the estrogenic effect correlates with estrone.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates; less than 5% as unchanged drug). Biliary/fecal elimination accounts for about 10%.
Renal (primarily as conjugated metabolites); approximately 50-80% of an oral dose is excreted in urine, with about 20% in feces via biliary elimination.
Category D/X
Category C
Estrogen
Estrogen